Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

J. Graggaber | G. Boehmer | G. Koduri | C. Pasquale | H. Parfrey | M. Fisk | J. Cheriyan | Mary A. Kasanicki | S. Kunhunny | E. Beranová | V. Mendoza | M. Kostapanos | Spoorthy Kulkarni | G. Lindergard | Sherly Jose | P. Mcalinden | Clemency Nye | C. Fox | S. Cathcart | A. Ioniță | A. Rajasekaran | Aileen Nacorda | Sam Bird | L. Broad | M. Bruce | J. Deery | T. Evans | A. Fielding | S. Gogoi | D. Nagra | J. Patrick | C. Price | E. Stephenson | J. Willis | D. Makkuni | Carrie Bayliss | Karen Burns | Evgenia Kourampa | A. Bermperi | Heike Templin | L. Canna | A. Meadows | A. Plumbe | Elena Hernan-Sancho | S. Tilbey | Lissamma Titti | Louise Stockley | Hugo Tordesillas | Jason Domingo | Kay Drury | W. Harrison | L. Mccormack | Jennifer Vidler | T. Hazelton | Donal Forde | Charlotte A. Bradbury | Estefania Treus | Sam Norton | Andrew Ustianowski | A. Barr | Simon Bond | D. Rimmer | G. Semple | L. Allen | A. Knight | S. Hey | K. Simpson | J. Underwood | K. Rahilly | D. Putensen | T. Lamb | V. Britten | K. Dorey | S. Frayling | N. Griffiths | M. Mercioniu | M. Nisar | A. Orme | S. Pilgrim | H. Thatcher | Claire Judd | A. Balan | H. Bayes | E. Cross | J. Flaherty | James Galloway | M. Haynes | C. Oliver | A. Uriel | K. Scott | Neil S. Sheerin | Andrew Cope | Arthur G Pratt | Jane Rowlands | G. Williams | Rhys Davies | J. Kellett | David Jayne | William G Petchey | Marianna Nodale | Shweta Bhagat | G. Coakley | S. Wright | Marwan Bukhari | Frances C Hall | I. Wilkinson | Edward Banham-Hall | Thomas Sheeran | Georgina Bird | Laura Gray | Tanwir Ahmed | Natalie Byrne | James Goodman | J. Gray | Tania Gudu | Ing Ni Lu | Peta Masters | Fraz Mir | Carmel Stober | Donna Abercrombie | Stella Burns | Kathy Hodges | Thelma Mushapaizdi | Debbie Read | Valentina Ruffulo | Carlotta Soave | Varun Sharma | Laurence Phiri | A. Moody | Susanna Crayton | Andrew Shah | Thrusha Jain | D. Kavanagh | Kelly Baldwin | Sunil Sharma | Kirsty Bracewell | Monika Musiol | Matthew Seal | L. Pollard | Sunil Gupta | Amelia Holloway | Anja Schmidtmann | Georgios K Dimitraidis | Debbie Devenport

[1]  D. Annane,et al.  Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial , 2023, The Lancet Respiratory Medicine.

[2]  F. Meziani,et al.  Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])* , 2022, Critical care medicine.

[3]  D. Annane,et al.  Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial , 2022, The Lancet Respiratory Medicine.

[4]  M. Moutschen,et al.  Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial , 2022, Respiratory Research.

[5]  M. Mansournia,et al.  A practical guide to handling competing events in etiologic time-to-event studies , 2022, Global epidemiology.

[6]  K. C. Morris,et al.  Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis , 2022, medRxiv.

[7]  G. Remuzzi,et al.  Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study , 2021, PloS one.

[8]  Brenda J. Crowe,et al.  Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial , 2021, The Lancet Respiratory Medicine.

[9]  Kenneth G. C. Smith,et al.  Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease , 2021, Immunity.

[10]  I. Wilkinson,et al.  Baricitinib set to join the Covid-19 therapeutic arsenal? , 2021, Rheumatology.

[11]  H. Moch,et al.  SARS-CoV-2 leads to a small vessel endotheliitis in the heart , 2021, EBioMedicine.

[12]  Cameron R. Wolfe,et al.  Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, New England Journal of Medicine.

[13]  R. Wells,et al.  One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab , 2020, European journal of haematology.

[14]  G. Nuovo,et al.  Severe COVID-19: A multifaceted viral vasculopathy syndrome , 2020, Annals of Diagnostic Pathology.

[15]  Thomas Jaki,et al.  Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report , 2020, The New England journal of medicine.

[16]  I. Wilkinson,et al.  Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[17]  Christoph B. Messner,et al.  Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection , 2020, Cell Systems.

[18]  Kai Chen,et al.  Endotheliitis and Endothelial Dysfunction in Patients with COVID-19: Its Role in Thrombosis and Adverse Outcomes , 2020, Journal of clinical medicine.

[19]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[20]  A. Shah,et al.  A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study , 2020, Journal of Infection.

[21]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[22]  Z. Dai,et al.  Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis , 2020, Journal of Clinical Virology.

[23]  Lisa E. Gralinski,et al.  Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis , 2018, mBio.

[24]  Shibo Jiang,et al.  Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV , 2018, Emerging Microbes & Infections.

[25]  K. Chapman,et al.  The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights , 2011, Molecular and Cellular Endocrinology.

[26]  J. Peiris,et al.  Mannose-Binding Lectin in Severe Acute Respiratory Syndrome Coronavirus Infection , 2005, The Journal of infectious diseases.

[27]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[28]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[29]  Louis Coetzee,et al.  Contents , 2011, 2011 6th International Conference on Pervasive Computing and Applications.